Key result
Intravenous administration of the endothelin-1 antagonist BQ-123 did not reduce myocardial infarct size compared to saline in a dog model of ischemia.
Why the study?
Does intravenous BQ-123 reduce myocardial infarct size in a dog model of ischemia/reperfusion injury?
Does intravenous BQ-123 reduce myocardial infarct size in a dog model of ischemia/reperfusion injury?
Intravenous administration of the endothelin-1 antagonist BQ-123 does not protect against ischemia/reperfusion injury in a canine model of acute coronary occlusion.
Answers are grounded in this paper and cite their sources.
Endothelin ETA blockade merits further study in ischaemia-reperfusion models; leaves open any clinical role in myocardial injury.
OBJECTIVE: It has been proposed that myocardial ischaemic injury is modulated in part by the release of endothelin-1 from the coronary endothelium either during ischaemia or following reperfusion. Release of sufficient amounts of endothelin-1 would result in coronary vasoconstriction and could potentiate ischaemic damage. An endothelin-1 antagonist, BQ-123, was given intravenously to evaluate the role of endothelin-1 in postischaemic injury and determine whether blockade of the ETA receptor would afford protection from ischaemia/reperfusion injury. METHODS: Myocardial injury was induced in anaesthetised dogs using 90 min of left circumflex coronary artery occlusion followed by 4 h of reperfusion. Animals treated with a continuous intravenous infusion of BQ-123 (0.1 mg.kg-1.min-1), begun 10 min before ischaemia and continued throughout ischaemia and reperfusion, were compared to saline treated animals. RESULTS: After 4 h of reperfusion the myocardial infarct size measured by triphenyltetrazolium chloride staining was not different between the two groups. Infarct size in the control group was 25.7 (SEM 5.4)% of the area at risk while BQ-123 treatment resulted in an infarct size of 29.2(7.1)% of the area at risk (p = 0.70). Plasma endothelin-1 concentration measured at the coronary sinus was only significantly increased following 5 min of reperfusion. CONCLUSIONS: The intravenous administration of a specific ETA receptor antagonist does not protect against ischaemia/reperfusion injury. These results suggest that endothelin-1 receptor antagonists require access to the area at risk during occlusion to protect the myocardium from ischaemic injury.
No takes yet. Share an insight, caveat, or question.
Krause et al. (1994) studied Myocardial ischaemic injury. BQ-123 vs. Saline was evaluated on Myocardial infarct size (% of the area at risk) (p=0.70). Intravenous administration of the endothelin-1 antagonist BQ-123 did not reduce myocardial infarct size compared to saline in a dog model of ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: